Search

To meet the requirements of biomedical applications in the antibacterial realm, it is of great importance to explore nano-antibiotics for wound disinfection that can prevent the development of drug resistance and possess outstanding biocompatibility. Therefore, we attempted to synthesize an atomically dispersed ion (Fe) on phenolic carbon quantum dots (CQDs) combined with an organic photothermal agent (PTA) (Fe@SAC CQDs/PTA) via a hydrothermal/ultrasound method. Fe@SAC CQDs adequately exerted peroxidase-like activity while the PTA presented excellent photothermal conversion capability, which provided enormous potential in antibacterial applications. Based on our work, Fe@SAC CQDs/PTA exhibited excellent eradication of Escherichia coli (>99% inactivation efficiency) and Staphylococcus aureus (>99% inactivation efficiency) based on synergistic chemodynamic therapy (CDT) and photothermal therapy (PTT). Moreover, in vitro experiments demonstrated that Fe@SAC CQDs/PTA could inhibit microbial growth and promote bacterial biofilm destruction. In vivo experiments suggested that Fe@SAC CQDs/PTA-mediated synergistic CDT and PTT exhibited great promotion to wound disinfection and recovery effects. This work indicated that Fe@SAC CQDs/PTA could serve as a broad-spectrum antimicrobial nano-antibiotic, which was simultaneously beneficial for bacterial biofilm eradication, wound disinfection, and wound healing. © 2024 American Chemical Society.

Chemodynamic therapy (CDT) is a highly targeted approach to treat cancer since it converts hydrogen peroxide into harmful hydroxyl radicals (OH & BULL;) through Fenton or Fenton-like reactions. However, the systemic toxicity of metal-based CDT agents has limited their clinical applications. Herein, a metal-free CDT agent: 2,4,6-tri(4-pyridyl)-1,3,5-triazine (TPT)/ [closo-B12H12]2-(TPT@ B12H12) is reported. Compared to the traditional metal-based CDT agents, TPT@B12H12 is free of metal avoiding cumulative toxicity during long-term therapy. Density functional theory (DFT) calculation revealed that TPT@B12H12 decreased the activation barrier more than 3.5 times being a more effective catalyst than the Fe2+ ion (the Fenton reaction), which decreases the barrier about twice. Mechanismly, the theory calculation indicated that both [B12H12]-& BULL; and [TPT-H]2+ have the capacity to decompose hydrogen into 1O2, OH & BULL;, and O2-& BULL;. With electron paramagnetic resonance and fluorescent probes, it is confirmed that TPT@B12H12 increases the levels of 1O2, OH & BULL;, and O2-& BULL;. More importantly, TPT@B12H12 effectively suppress the melanoma growth both in vitro and in vivo through 1O2, OH & BULL;, and O2-& BULL; generation. This study specifically highlights the great clinical translational potential of TPT@B12H12 as a CDT reagent. 2,4,6-Tri(4-pyridyl)-1,3,5-triazine (TPT)/ [closo-B12H12]2-(TPT@B12H12), a metal-free chemodynamic therapy (CDT) agent, decreases the activation barrier more than 3.5 times being a more effective catalyst than the Fe2+ ion (the Fenton reaction), which decreases the barrier about twice. More importantly, TPT@B12H12 effectively suppress the melanoma growth both in vitro and in vivo through 1O2, OH & BULL;, and O2-& BULL; generation. image

The treatment of infected diabetic wounds faces severe challenges due to vascular deficiencies induced by a hyperglycemia microenvironment and the extensive proliferation of drug-resistant bacteria. In this work, we developed a glucose-responsive hydrogel dressing system (CGH) with dual properties that effectively treat methicillin-resistant Staphylococcus aureus (MRSA)-infected wounds in rats and enhance wound healing. The hydrogel is synthesized using copper nanoclusters (CuNCs) cross-linked with oxidized hyaluronic acid (HA-ALD) in situ and decorated with glucose oxidase (GOx). GOx enzymatically degrades excess glucose at the wound site, generating gluconic acid and H2O2, and optimizes the limiting factors of the Fenton reaction. Decreasing pH weakens the interaction between CuNCs and HA-ALD, resulting in the release of CuNCs that catalyze the production of reactive oxygen species (ROS) by degradation of H2O2 through the Fenton reaction. This process can eradicate drug-resistant bacteria. In addition, CuNCs endowed hydrogels with excellent conductivity, thus enabling the promotion of blood vessel formation by electrical stimulation (ES), thereby facilitating tissue repair around the wound area. In conclusion, the developed novel multifunctional wound healing system can conform to irregular wound shapes, reduce glucose levels within the wound, establish a sustained sterile environment, and promote blood vessel formation through electrical stimulation, thus emerging as a highly promising and comprehensive option for effectively treating complex diabetic wounds.

Combinations of different therapeutic strategies, including chemotherapy (CT), chemodynamic therapy (CDT), and photothermal therapy (PTT), are needed to effectively address evolving drug resistance and the adverse effects of traditional cancer treatment. Herein, a camouflage composite nanoformulation (TCBG@PR), an antitumor agent (tubercidin, Tub) loaded into Cu-doped bioactive glasses (CBGs) and subsequently camouflaged by polydopamine (PDA), and red blood cell membranes (RBCm), was successfully constructed for targeted and synergetic antitumor therapies by combining CT of Tub, CDT of doped copper ions, and PTT of PDA. In addition, the TCBG@PRs composite nanoformulation was camouflaged with a red blood cell membrane (RBCm) to improve biocompatibility, longer blood retention times, and excellent cellular uptake properties. It integrated with long circulation and multimodal synergistic treatment (CT, CDT, and PTT) with the benefit of RBCms to avoid immune clearance for efficient targeted delivery to tumor locations, producing an “all-in-one” nanoplatform. In vivo results showed that the TCBG@PRs composite nanoformulation prolonged blood circulation and improved tumor accumulation. The combination of CT, CDT, and PTT therapies enhanced the antitumor therapeutic activity, and light-triggered drug release reduced systematic toxicity and increased synergistic antitumor effects., SCOPUS: ar.j, info:eu-repo/semantics/published

Leptomeningeal carcinomatosis (LMC) is a severe complication of cancers that markedly shortens survival and lowers the quality of patients’ life, and it still lacks adequate therapeutic programs. Nanomedicine-mediated therapy has recently presented promising to treat malignant tumors, whereas it remains challenging to deliver nanomedicines for high-efficacy LMC treatment owing to the existence of brain-related delivery barriers. Herein, a novel and effective strategy of combined sonodynamic/chemodynamic therapy (SDT/CDT) of LMC by intrathecal injection of a tumor-targeted metalloporphyrin-integrated nanosystem (MOF@MP-RGD) is developed for the first time. Thereinto, intrathecal administration can directly transport such nanosystems into the cerebrospinal fluid (CSF) around the brain and spinal cord to overcome the brain-related barriers for improving delivery. By building of the orthotopic LMC model, the nanosystems are demonstrated to be effectively accumulated in the LMC area post intrathecal administration due to the arginine-glycine-aspartate (RGD) active targeting, and subsequently excreted out of the body by metabolism process. In vivo evaluations reveal the desirable LMC tumor inhibition and survival prolongation of the combined SDT/CDT based on such biocompatible nanosystems, that is superior to the clinically-used chemotherapeutic drug. Therefore, the combination of intrathecal delivery and nanomedicine-mediated therapy holds great potential for clinical LMC treatment.